EPIX options novel imaging agent to Schering
This article was originally published in Clinica
German pharmaceuticals company Schering has exercised its option, under a previously-signed joint research agreement, with EPIX Pharmaceuticals to develop a novel imaging candidate indicated for diagnosing atherosclerosis and other vascular diseases.
You may also be interested in...
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.